Dehghani Seyed Mohsen, Eshraghian Ahad, Bahador Ali, Kakaei Farzad, Geramizadeh Bita, Malek-Hosseini Seyed Ali
Shiraz Transplant Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.
Exp Clin Transplant. 2009 Sep;7(3):145-8.
The improvement of pre-existing inflammatory bowel disease after orthotopic liver transplant might be anticipated. However, both the exacerbation of inflammatory bowel disease and de novo inflammatory bowel disease after orthotopic liver transplant (despite sufficient allograft immunosuppressive therapy) have been described.
We present a case of ulcerative colitis in a pediatric liver transplant recipient.
A 13-year-old boy with cryptogenic liver cirrhosis received an orthotopic liver transplant from a deceased donor. Five months later, he presented with watery diarrhea and abdominal distention. He was treated with the immunosuppressive agents tacrolimus (0.15 mg/kg/d) and mycophenolate mofetil (20 mg/kg/d). A general physical examination revealed a boy with stable vital signs and without fever. The only positive finding was enlargement of the abdomen without tenderness. Many pus cells and a few red blood cells were detected in the patient's stool, but the results of a stool culture for bacteria were negative. Because of his chronic diarrhea, this patient underwent colonoscopy, which revealed diffuse erythematous mucosa, multiple ulcers, exudate, and pseudopolyps with a diffuse loss of vascularity. Those findings are indicators of colitis. The results of histopathologic examination of the colonic mucosa suggested ulcerative colitis. The patient was treated with mesalamine and prednisolone, and a repeat colonoscopy revealed an improvement in his bowel disease.
De novo inflammatory bowel disease should be considered in patients in whom chronic diarrhea develops after an orthotopic liver transplant. We suggest that colonoscopy and biopsy should always be performed if other causes of diarrhea have been excluded.
原位肝移植后原有炎症性肠病可能会有所改善。然而,也有原位肝移植后炎症性肠病加重以及新发炎症性肠病(尽管给予了充分的同种异体移植免疫抑制治疗)的相关报道。
我们报告一例小儿肝移植受者患溃疡性结肠炎的病例。
一名13岁患有隐源性肝硬化的男孩接受了来自已故供体的原位肝移植。五个月后,他出现水样腹泻和腹胀。给予他免疫抑制剂他克莫司(0.15毫克/千克/天)和霉酚酸酯(20毫克/千克/天)进行治疗。全身体格检查显示该男孩生命体征平稳,无发热。唯一的阳性发现是腹部膨隆但无压痛。在患者粪便中检测到许多脓细胞和少量红细胞,但粪便细菌培养结果为阴性。由于他长期腹泻,该患者接受了结肠镜检查,结果显示黏膜弥漫性红斑、多处溃疡、渗出物以及假息肉,伴有弥漫性血管消失。这些发现是结肠炎的指标。结肠黏膜组织病理学检查结果提示为溃疡性结肠炎。该患者接受了美沙拉嗪和泼尼松龙治疗,再次结肠镜检查显示其肠道疾病有所改善。
原位肝移植后出现慢性腹泻的患者应考虑新发炎症性肠病。我们建议,如果已排除腹泻的其他原因,应始终进行结肠镜检查和活检。